Meros Investment Management LP Makes New $419,000 Investment in Sensus Healthcare, Inc. $SRTS

Key Points

• Meros Investment Management LP acquired 88,478 shares of Sensus Healthcare, Inc. for approximately $419,000, representing a 0.54% stake in the company.
• Sensus Healthcare's stock price fell by 2.6% to $3.35, with a twelve-month high of $9.33 and a low of $3.03.
• The company reported a loss of $0.06 earnings per share for the last quarter, missing the analyst estimate of $0.01, and had revenue of $7.32 million, below expectations of $9.30 million.

Meros Investment Management LP acquired a new stake in Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 88,478 shares of the company's stock, valued at approximately $419,000. Meros Investment Management LP owned about 0.54% of Sensus Healthcare at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Renaissance Technologies LLC grew its holdings in Sensus Healthcare by 5.3% during the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock worth $2,982,000 after acquiring an additional 21,600 shares during the period. Dimensional Fund Advisors LP grew its holdings in Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock worth $2,620,000 after acquiring an additional 88,953 shares during the period. Bank of New York Mellon Corp grew its holdings in Sensus Healthcare by 3.9% during the first quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock worth $672,000 after acquiring an additional 5,289 shares during the period. Marshall Wace LLP grew its holdings in Sensus Healthcare by 99.6% during the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company's stock worth $915,000 after acquiring an additional 65,994 shares during the period. Finally, Sachetta LLC grew its holdings in Sensus Healthcare by 4.1% during the first quarter. Sachetta LLC now owns 124,887 shares of the company's stock worth $591,000 after acquiring an additional 4,945 shares during the period. Institutional investors and hedge funds own 25.30% of the company's stock.

Sensus Healthcare Price Performance

NASDAQ:SRTS traded up $0.0450 during mid-day trading on Thursday, reaching $3.2850. The company's stock had a trading volume of 23,955 shares, compared to its average volume of 189,374. The company's fifty day simple moving average is $4.58 and its two-hundred day simple moving average is $4.80. Sensus Healthcare, Inc. has a twelve month low of $3.03 and a twelve month high of $9.33. The stock has a market cap of $54.01 million, a P/E ratio of -54.67 and a beta of 1.34.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.07). Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.The business had revenue of $7.32 million during the quarter, compared to analyst estimates of $9.30 million. Sell-side analysts expect that Sensus Healthcare, Inc. will post 0.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the company. Wall Street Zen lowered Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd. HC Wainwright lowered their target price on Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. Maxim Group lowered their target price on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Finally, Lake Street Capital lowered their target price on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $8.00.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.